Found: 7
Select item for more details and to access through your institution.
Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 8, p. 1, doi. 10.1111/cts.13895
- By:
- Publication type:
- Article
Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 104, doi. 10.1007/s10637-013-9953-8
- By:
- Publication type:
- Article
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
- Published in:
- Gastric Cancer, 2014, v. 17, n. 1, p. 161, doi. 10.1007/s10120-013-0247-9
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 4, p. 1, doi. 10.1111/cts.13784
- By:
- Publication type:
- Article
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article